The Senate Special Committee on Aging today concluded a two-part hearing on the impact of rising prescription drug costs on seniors and potential policy solutions.
 
Stacie Dusetzina, an associate professor of health policy at Vanderbilt University Medical Center in Nashville, Tenn., who participated on a National Academy of Medicine committee that issued a 2017 report on strategies for making prescription drugs more affordable, urged the Senate committee to focus on three key goals: ensuring that patients can access high-value drugs at reasonable out-of-pocket costs; removing incentives for high list prices and price increases; and rewarding true innovation by pharmaceutical companies by paying for value.

Also testifying at the hearing were representatives from Consumer Reports, Point-of-Care Partners and Horvath Health Policy.
 
The House Ways and Means Health Subcommittee also held a hearing today focused on promoting competition to lower Medicare drug prices. Witnesses included representatives from the Institute for Innovation Law at the University of California Hastings School of Law; Program on Regulation, Therapeutics and Law at Harvard Medical School; Global Health Justice Partnership at Yale Law School; Families USA; and American Action Forum.
 
AHA has recommended a number of policy solutions to restrain drug prices, from addressing anticompetitive actions by brand-name drug manufacturers to speeding up generic drug approvals and passing the CREATES Act.

Related News Articles

Headline
The House Energy and Commerce Subcommittee on Health today held a hearing on seven bills aimed at improving transparency in the drug supply chain to lower…
Headline
he House of Representatives last night voted 234-183 to pass legislation (H.R. 987) that combines several AHA-supported bills to help lower prescription drug…
Headline
The Centers for Medicare…
Blog
Drug companies are at it again. And their latest effort to divert the focus from the huge profits they pocket as drug prices rise is just as disingenuous as…
Headline
The largest U.S. pharmaceutical and biotech companies spend just 22 cents out of every dollar on research and development, according to an analysis released…
Headline
The House Energy and Commerce Subcommittee on Health today held a hearing on lowering prescription drugs prices, which focused on the drug supply chain.